News

: CureVac stock drops more than 50% on news trial COVID vaccine 47% effective

Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.

Curevac’s
CVAC,
-3.47%

messenger RNA-based vaccine would compete with similar vaccines from Pfizer and BioNTech as well as Moderna, which have shown efficacy above 90% and have already been distributed to millions of people across the globe.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News